Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

First International Summit on Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Opportunities to Optimize Cancer Policies Panel Discussion

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Cost of Care

The ASCO Post Staff

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

Nov

Today In Oncology

Long-Term Survivors of Hodgkin Lymphoma May Face Elevated Health Risks, Study Finds

OptiTROP-Lung06 A Potential Alternative to Chemotherapy in Advanced PD-L1–Negative NSCLC?

Ponatinib/Blinatumomab Improves Event-Free Survival in Ph-Positive ALL

American Lung Association and Prevent Cancer Foundation Host Virtual QIW Workshop: Advancing Routine Clinical Use of Health Information From Chest CT Screening for Public Health